This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biotech Stock Roundup: BIIB Posts Q3 Results, VRTX Stops Study & Other Updates
by Zacks Equity Research
The biotech sector was in focus as Biogen's (BIIB) Q3 results disappoint, Vertex (VRTX) stops study and Regeneron's (REGN) Ebola drug gets FDA approval.
Healthcare to Post Solid Q3 Earnings Growth: ETFs in Focus
by Sweta Killa
The healthcare is expected to witness substantial earnings growth of 5.1% in the third quarter, representing the second strongest sector this earnings season.
Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Lilly (LLY) Witness Recovery in Sales in Q3 Earnings?
by Zacks Equity Research
Higher demand for its growth drugs is likely to have offset generic competition for several other drugs to boost Lilly's (LLY) third-quarter sales.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $60.55, marking a -0.03% move from the previous day.
Gilead's (GILD) CAR T Cell Therapy Gets Positive CHMP Opinion
by Zacks Equity Research
Gilead (GILD) gets positive CHMP opinion for KTE-X19, a chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory mantle cell lymphoma.
Why You Should Invest in Genomics ETFs
by Neena Mishra
Genomics ETFs have surged of late; here's why
Regeneron's (REGN) Inmazeb Ebola Treatment Gets FDA Approval
by Zacks Equity Research
Regeneron (REGN) gets FDA nod for its triple antibody cocktail for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients.
Stocks Down 2nd Straight Day: Prime, Lilly, United Q3 & More
by Mark Vickery
Market indexes closed lower for their second-straight session, following a string of four days in a row higher.
Biotech Stock Roundup: REGN, GILD's Coronavirus News & Other Pipeline Updates
by Zacks Equity Research
Regeneron (REGN) and Gilead (GILD) continue to be in the spotlight on coronavirus-related updates.
Lilly's Coronavirus Antibody Study Paused on Safety Concerns
by Zacks Equity Research
Lilly (LLY) is developing antibody candidates for a potential COVID-19 treatment in several clinical studies.
Gilead Sciences (GILD) Stock Moves -0.09%: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $64.49 in the latest trading session, marking a -0.09% move from the prior day.
Gilead & Galapagos Announce Positive Data on UC Candidate
by Zacks Equity Research
Gilead (GILD) and partner Galapagos report positive data on filgotinib for the indication of active ulcerative colitis.
Lilly's Mirikizumab Retains Efficacy in Crohn's Disease Study
by Zacks Equity Research
Eli Lilly's (LLY) mirikizumab continues to show symptom improvement and reduction of intestinal mucosal inflammation in Crohn's disease patients after a year-long treatment in a mid-stage study.
AstraZeneca's Coronavirus Antibody Therapy to Enter Late Stage
by Zacks Equity Research
AstraZeneca (AZN) plans to start two phase III studies in October for evaluating its cocktail antibody therapy for COVID-19. To this end, the company gets $486 million funding from the U.S. government.
Gilead Up on Positive Final Results for Coronavirus Treatment
by Zacks Equity Research
Gilead (GILD) gains on results from the phase III ACTT-1 study of investigational antiviral Veklury for the treatment of adults hospitalized with mild-moderate or severe COVID-19.
Stock Market News for Oct 12, 2020
by Zacks Equity Research
Wall Street closed higher on Friday buoyed by market participants' expectations for a full-phased fresh fiscal stimulus before the upcoming U.S. presidential election.
Regeneron Gains on EUA Request for Coronavirus Treatment
by Zacks Equity Research
Regeneron's (REGN) stock up following the submission of a request to the FDA for granting an Emergency Use Authorization to its experimental COVID-19 treatment, REGN-COV2.
Lilly Seeks Emergency Use of Coronavirus Antibody Candidate
by Kinjel Shah
Lilly (LLY) applies to the FDA for Emergency Use Authorization of antibody therapy, LYCoV555. Releases promising data which shows that an antibody combination, LYCoV555 and LY-CoV016, is effective.
The Zacks Analyst Blog Highlights: Gilead, JNJ, Sanofi, BMY and MyoKardia
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead, JNJ, Sanofi, BMY and MyoKardia
Biotech Stock Roundup: ALXN to Raise Guidance, BMY to Buy MYOK & Other Updates
by Zacks Equity Research
The biotech sector remains in focus with regulatory, acquisition and other pipeline updates.
Current Outlook Gloomy
by Zacks Equity Research
Current Outlook Gloomy
A Murky Way Forward, Plus Lilly's New Candidate
by Mark Vickery
There is plenty to address in the coming weeks and months, though not much will be moving the needle this morning.
Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $62.52, moving -1.7% from the previous trading session.
DICK'S, Las Vegas Sands, Regeneron, Gilead and Eli Lilly as Zacks Bull and Bear of the Day
by Zacks Equity Research
DICK'S, Las Vegas Sands, Regeneron, Gilead and Eli Lilly as Zacks Bull and Bear of the Day